NCT01363050View on ClinicalTrials.gov

Study to Determine the Tolerability, Safety and Pharmacokinetics of Ketorolac Tromethamine by Intranasal Administration in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

February 28, 2006

Study Completion Date

September 30, 2006

Conditions

Healthy Volunteers

Interventions

DRUG

Ketorolac tromethamine

Subjects received intranasal ketorolac tromethamine (30 mg) three times daily (t.i.d.) for three days (seven doses in total). Doses were administered every eight hours.

Trial Locations (1)

Unknown

Medeval Limited, Manchester